Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.42), $0.11 better than the analyst estimate of ($0.53). Revenue for the quarter came in at $106.6 million versus the consensus estimate of $111.63 million.

Reiterating FY21 net sales guidance of $510 to $550 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.